AbbVie Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

AbbVie stock holds near its 52-week high

AI-generated analysis

📈 AbbVie stock closed at USD 263.52 on September 19, 2026, trading just below its 52-week high of USD 267.47.

💰 Second-quarter revenue surged to USD 16.99 billion, marking a 10.16 percent year-over-year increase.

📊 Adjusted earnings per share jumped significantly to USD 2.03 in the second quarter compared to USD 0.52 last year.

🎯 Analyst consensus price target is set at USD 277.31, implying roughly 5.64 percent upside from current levels.

⚖️ Valuation models indicate overvaluation, with GF Value suggesting a fair price of USD 220.69 versus the market price of USD 264.02.

📉 Trading volume reached 8.18 million shares on September 19, reflecting active investor interest near yearly highs.

🗓️ The next earnings report is scheduled for release on October 23, 2026.

Bullish Signals
  • AbbVie reported robust second-quarter revenue growth of 10.16 percent to USD 16.99 billion, demonstrating strong top-line performance.
  • Adjusted earnings per share more than tripled year-over-year to USD 2.03, highlighting significant profitability improvement.
  • The stock is trading near its 52-week high of USD 267.47 with a market cap of USD 466.34 billion, indicating strong investor confidence.
  • Analyst consensus price target of USD 277.31 suggests potential upside of 5.64 percent from current trading levels.
Risk Factors
  • Valuation metrics suggest the stock is overvalued, with GF Value indicating a 19.6 percent premium to its calculated fair value of USD 220.69.
  • The stock price has reached near-52-week highs, which may limit immediate upside potential and increase sensitivity to any earnings miss.
Full Analysis
AbbVie Inc. stock traded at USD 263.52 on September 19, 2026, holding near its 52-week high of USD 267.47 with a market capitalization of USD 466.34 billion. The company reported strong second-quarter financial results, posting adjusted earnings per share of USD 2.03 compared to USD 0.52 a year earlier, while revenue increased by 10.16 percent to reach USD 16.99 billion. Analyst consensus for AbbVie stands at USD 277.31, representing a potential upside of approximately 5.64 percent from the current trading price, with ratings generally leaning towards Buy. However, valuation metrics present a mixed picture, as the GF Value model suggests the stock is trading at a 19.6 percent premium to its fair value of USD 220.69. The pharmaceutical giant's shares saw a session volume of 8.18 million shares on September 19, with intraday activity reaching a high of USD 266.29. The next quarterly earnings report is scheduled for release on October 23, 2026, keeping investor attention focused on future guidance and performance trends.